No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Genexine, Inc. is a South Korean clinical-stage biotechnology firm dedicated to advancing and commercializing immunotherapeutics and extended-duration biologics. The company leverages two key proprietary technologies: the hyFc platform, engineered for discovering diverse agonistic protein therapeutics, and an Immune Enhancing Technology, which focuses on therapeutic DNA vaccines. Its extensive pipeline features several drug candidates: GX-H9, currently in Phase II trials for treating growth hormone deficiency in both adults and children; GX-E2, also in Phase II, addressing induced anemia; GX-G3, in Phase II for neutropenia; and GX-G6, undergoing Phase I studies for diabetes. Additionally, GX-188E is in Phase II clinical trials, being evaluated in combination with KEYTRUDA for cervical cancer treatment. Genexine has also forged a co-development alliance with Binex Co. Ltd. to create a COVID-19 vaccine. Founded in 1999 as Genexine Co., Ltd., the company adopted its current name, Genexine, Inc., in March 2013 and is headquartered in Seongnam, South Korea.
www.genexine.comNo one on the platform currently holds 095700.KQ.
No tracked institution reports a position in 095700.KQ as of their last filing.
No one on the platform has traded 095700.KQ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 56.0% | -24.4% | ||||
| Profit Margin % | -590.6% | -950.0% | -535.2% | |||
| Free Cash Flow Margin % | -969.0% | -586.7% | -414.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $15.7B | — | $-493.93 | $-493.93–$-493.93 | — | 1 |
| 2027 | $9.1B | -41.8% | $-991.69 | $-991.69–$-991.69 | — | 1 |
| 2028 | $19.1B | +109.7% | $-96.75 | $-96.75–$-96.75 | — | 1 |
| 2029 | $18.4B | -3.5% | $-1361.45 | $-1361.45–$-1361.45 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 5 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-18 | $157.81 | $-577.57 | -466.0% |
| 2026-05-18 | $157.81 | $-273.62 | -273.4% |
| 2026-02-02 | $157.81 | $-317.55 | -301.2% |
| 2025-11-12 | $-385.90 | $463.00 | +220.0% |
| 2025-08-14 | $-385.90 | $-323.29 | +16.2% |
| +0.51% |
| $135.1B |
| — |
| 092040.KQAmicogen, Inc. | $833.00 | +1.34% | $47.4B | — |
| 115450.KQHLB Therapeutics Co.,Ltd. | $1996.00 | +2.41% | $176.0B | — |
Source: Financial Modeling Prep · peers by sector/industry